stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) EBITDA
Palvella Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$38.6M, compared with −$14.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$57.7M. Over the past ten years it has ranged from −$49.4M (fiscal 2021) to −$11.9M (fiscal 2023); the current reading is higher than 27% of that period. Palvella Therapeutics, Inc. ranks 341st of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$38.6M | — |
| FY2024 | −$14.1M | — |
| FY2023 | −$11.9M | — |
| FY2022 | −$40.7M | — |
| FY2021 | −$49.4M | — |
| FY2020 | −$31.6M | — |
| FY2019 | −$26.5M | — |
| FY2018 | −$30.3M | — |
| FY2017 | −$14.2M | — |
| FY2016 | −$22.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$21.4M | — |
| Mar 2026 | −$14.9M | — |
| Dec 2025 | −$11.3M | — |
| Sep 2025 | −$10.2M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. | −$57.7M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement